CN104394881B - 修饰的人肿瘤坏死因子受体-1多肽的新用途 - Google Patents

修饰的人肿瘤坏死因子受体-1多肽的新用途 Download PDF

Info

Publication number
CN104394881B
CN104394881B CN201380032597.1A CN201380032597A CN104394881B CN 104394881 B CN104394881 B CN 104394881B CN 201380032597 A CN201380032597 A CN 201380032597A CN 104394881 B CN104394881 B CN 104394881B
Authority
CN
China
Prior art keywords
amino acid
tnfri
modified
acid sequence
dry eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380032597.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104394881A (zh
Inventor
金圣旭
朴胜国
宋连情
金银善
安惠敬
丁在甲
李亨根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Hanall Biopharma Co Ltd
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Publication of CN104394881A publication Critical patent/CN104394881A/zh
Application granted granted Critical
Publication of CN104394881B publication Critical patent/CN104394881B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201380032597.1A 2012-06-21 2013-02-07 修饰的人肿瘤坏死因子受体-1多肽的新用途 Active CN104394881B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120066527 2012-06-21
KR10-2012-0066527 2012-06-21
PCT/KR2013/000983 WO2013191352A1 (en) 2012-06-21 2013-02-07 New uses of modified human tumor necrosis factor receptor-1 polypeptide

Publications (2)

Publication Number Publication Date
CN104394881A CN104394881A (zh) 2015-03-04
CN104394881B true CN104394881B (zh) 2016-10-26

Family

ID=49768924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032597.1A Active CN104394881B (zh) 2012-06-21 2013-02-07 修饰的人肿瘤坏死因子受体-1多肽的新用途

Country Status (6)

Country Link
US (1) US9580490B2 (enExample)
JP (1) JP6087429B2 (enExample)
KR (1) KR101514238B1 (enExample)
CN (1) CN104394881B (enExample)
BR (1) BR112014031923B1 (enExample)
WO (1) WO2013191352A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6884755B2 (ja) 2015-05-01 2021-06-09 オーエヌエル セラピューティクス，インコーポレーテッド ペプチド組成物および使用方法
WO2017221128A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Methods of treating dry eye disease using tnf alpha antagonists
US20240059768A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer
KR20230131213A (ko) * 2021-01-14 2023-09-12 한올바이오파마주식회사 탄파너셉트 안과용 조성물을 이용한 안구건조증의 치료

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098136A1 (en) * 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
CN101883787A (zh) * 2008-05-30 2010-11-10 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
WO2011049350A2 (ko) * 2009-10-19 2011-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
WO2012036410A2 (ko) * 2010-09-13 2012-03-22 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6204270B1 (en) 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
PL218992B1 (pl) 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
CN103370334B (zh) * 2010-12-23 2016-06-22 韩诺生物制药株式会社 修饰的人肿瘤坏死因子受体-i多肽或其片段及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098136A1 (en) * 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
CN101883787A (zh) * 2008-05-30 2010-11-10 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
WO2011049350A2 (ko) * 2009-10-19 2011-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
WO2012036410A2 (ko) * 2010-09-13 2012-03-22 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법

Also Published As

Publication number Publication date
BR112014031923B1 (pt) 2022-02-08
WO2013191352A1 (en) 2013-12-27
BR112014031923A2 (pt) 2017-11-28
JP6087429B2 (ja) 2017-03-01
US20150119338A1 (en) 2015-04-30
KR20130143484A (ko) 2013-12-31
US9580490B2 (en) 2017-02-28
CN104394881A (zh) 2015-03-04
JP2015525237A (ja) 2015-09-03
KR101514238B1 (ko) 2015-04-28

Similar Documents

Publication Publication Date Title
CN103221422B (zh) 嵌合il‑1受体i型激动剂和拮抗剂
US11382951B2 (en) Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
US6838429B2 (en) Atopic dermatitis treatment method
CN104394881B (zh) 修饰的人肿瘤坏死因子受体-1多肽的新用途
JP2014522868A (ja) 精製タンパク質
KR102653532B1 (ko) 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도
CA3206854A1 (en) Ulinastatin polypeptides for treating diseases
CN110891591A (zh) 用于治疗干眼症的包含甘氨酸-胸腺素β4(Gly-Tβ4)的药物组合物
JPWO2016104436A1 (ja) サイトカインストーム抑制剤
CN104371003A (zh) 预防和治疗炎症的小分子多肽及其应用
CN116253776B (zh) 靶向抑制trib3的多肽及其用途
CN111686241A (zh) Il-38蛋白在制备治疗眼科疾病的药物中的应用
HK40051700A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210420

Address after: Han Guodatianshi

Patentee after: HANALL BIOPHARMA Co.,Ltd.

Patentee after: DAEWOONG PHARMACEUTICAL Co.,Ltd.

Address before: Han Guodatianshi

Patentee before: HANALL BIOPHARMA Co.,Ltd.

TR01 Transfer of patent right